Speciality
Spotlight

 




 


Oncology


 

 





Stem Cell Transplantation

   

  • Ann E Traynor, James Schroeder, et al (Division of Immunotherapy for Autoimmune Diseases, Northwestern University Chicago, USA)

    Treatment of severe systemic lupus erythematosus with high-dose chemotherapy and haemopoietic stem-cell transplantation: a phase I study.

    The Lancet, vol.356, August 26, 2000. Pg.701-707.

       

    Patients with SLE and persistent multiorgan dysfunction, inspite of IV cyclophosphamide, have a high risk of early death. In this study, safety and efficacy of immune suppression and autologous haemopoietic stem-cell infusion was investigated.

      

    Seven selected patients with persistent SLE despite use of cyclophosphamide, underwent immune-suppression and autologous haemopoietic stem-cell (CD34) infusion. They mobilised autologous haemopoietic stem cells with cyclophosphamide and granulocyte colony stimulating factor, enriched with CD34-positive selection and reinfused after immunosuppression with cyclo phosphamide, methylprednisolone and equine antithymocyte globulin.

      

    At a median follow-up of 25 months, all patients were free from signs of lupus. Renal, cardiac, pulmonary and serological markers and T-cell phenotype and repertoire had normalized. Durability of remission remains to be established.

        


 

 



 

 

Speciality Spotlight

 

 

Stem Cell Transplantation
   

  • Ann E Traynor, James Schroeder, et al (Division of Immunotherapy for Autoimmune Diseases, Northwestern University Chicago, USA)
    Treatment of severe systemic lupus erythematosus with high-dose chemotherapy and haemopoietic stem-cell transplantation: a phase I study.
    The Lancet, vol.356, August 26, 2000. Pg.701-707.
       
    Patients with SLE and persistent multiorgan dysfunction, inspite of IV cyclophosphamide, have a high risk of early death. In this study, safety and efficacy of immune suppression and autologous haemopoietic stem-cell infusion was investigated.
      
    Seven selected patients with persistent SLE despite use of cyclophosphamide, underwent immune-suppression and autologous haemopoietic stem-cell (CD34) infusion. They mobilised autologous haemopoietic stem cells with cyclophosphamide and granulocyte colony stimulating factor, enriched with CD34-positive selection and reinfused after immunosuppression with cyclo phosphamide, methylprednisolone and equine antithymocyte globulin.
      
    At a median follow-up of 25 months, all patients were free from signs of lupus. Renal, cardiac, pulmonary and serological markers and T-cell phenotype and repertoire had normalized. Durability of remission remains to be established.
        

 

 

 

By |2022-07-20T16:43:57+00:00July 20, 2022|Uncategorized|Comments Off on Stem Cell Transplantation

About the Author: